HSP90AA1 and nasopharyngeal carcinoma: AT13387, a ground-breaking Hsp90 inhibitor, can restrain Hsp90 molecular chaperone function, downregulate HDAC6 and then increase the acetylation and stabilization of α-tubulin, ultimately suppressing nasopharyngeal carcinoma (NPC) oncogenesis and progression (Chan et al. 2013).